SGHT
Sight Sciences, Inc.
$5.02
0.00%
$273.1M
No data for this timeframe.
Vol
Market Cap$273.1M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (71%)
Inst. Holders50 funds
Inst. Value$33.6M
Inst. Activity10 buys / 5 sells
Insider Activity1B / 7S
Insider Net $-$308.2K
SEC Reports4
Press Releases1
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001531177·Prev Close $5.02
Recent Activity
Jun 10, 2026
Insider
Encrantz Staffan bought 14,100 shares
Director @ $4.88 ($68.8K)
Jun 4, 2026
Insider
Fountain Tamara was granted 28,261 shares
Director
Jun 4, 2026
Insider
Mazzacco Catherine was granted 28,261 shares
Director
May 6, 2026
earnings
Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance
<p align="justify">MENLO PARK, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasd
Apr 23, 2026
SEC
Sight Sciences (SGHT) announced a final court judgment in its patent infringement lawsuit against Alcon, awarding the co
8-K — Impact 8/10
Apr 21, 2026
SEC
Sight Sciences announced it will report Q1 2026 financial results on May 6, 2026, after market close, followed by a conf
PRESS-RELEASE — Impact 3/10
Apr 3, 2026
SEC
Two insiders at Sight Sciences, including CEO Badawi Paul, sold shares in a coordinated cluster totaling $119K over a 7-
CLUSTER — Impact 5/10
Inst.
Russell Investments Group, Ltd. — DOUBLED
205,999 shares ($776.6K)
Price Targets
$8.54
+70.1% upside
Strong Buy
Current $5.02
Low $5.15
Median $8.50
High $12.00
4 analysts
$5.15
$12.00
Analyst Ratings
4Strong Buy
6Buy
4Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 28, 2026 | Citigroup | MAINTAIN | Neutral → Neutral |
| Mar 6, 2026 | UBS | MAINTAIN | Buy → Buy |
| Mar 6, 2026 | Citigroup | MAINTAIN | Neutral → Neutral |
| Mar 2, 2026 | Stifel | MAINTAIN | Buy → Buy |
| Jan 5, 2026 | Piper Sandler | UPGRADE | Neutral → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.17 ▲ +1.9% | $-0.17 — $-0.17 | 26% YoY | 1 |
| Next Q | $-0.18 ▼ -12.5% | $-0.18 — $-0.18 | -13% YoY | 1 |
| Current FY | $-0.76 ▼ -13.4% | $-0.76 — $-0.76 | 4% YoY | 1 |
| Next FY | $-0.66 ▼ -18.6% | $-0.66 — $-0.66 | 13% YoY | 1 |
Latest Reports
BULLISH
8-K
8/10
Sight Sciences (SGHT) announced a final court judgment in its patent infringement lawsuit against Alcon, awarding the co
Apr 23, 2026
NEUTRAL
PRESS-RELEASE
3/10
Sight Sciences announced it will report Q1 2026 financial results on May 6, 2026, after market close, followed by a conf
Apr 21, 2026
MIXED
Press
6/10
Sight Sciences reported Q4 and full-year 2025 results with mixed performance: Q4 revenue grew 7% to $20.4 million, drive
Mar 4, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $10.7M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $5.5M | — |
| STATE STREET CORP | $3.1M | — |
| DIMENSIONAL FUND ADVISORS LP | $1.3M | ADD |
| D. E. Shaw & | $1.2M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 10, 2026 | Encrantz Staffan | BUY | $68.8K |
| Jun 4, 2026 | Fountain Tamara | A | $0.00 |
| Jun 4, 2026 | Mazzacco Catherine | A | $0.00 |
| Jun 4, 2026 | Zurbay Donald | A | $0.00 |
| Jun 4, 2026 | Burbach Gerhard | A | $0.00 |
50 institutional holders with $33.6M total value (8,881,221 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, STATE. Net buying activity: 10 institutions added/increased vs 5 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 2,831,932 | $10.7M | 31.7% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 1,452,690 | $5.5M | 16.3% | — |
| 3 | STATE STREET CORP | 835,028 | $3.1M | 9.4% | — |
| 4 | DIMENSIONAL FUND ADVISORS LP | 341,681 | $1.3M | 3.8% | ADD +79.4% |
| 5 | D. E. Shaw & Co., Inc. | 311,374 | $1.2M | 3.5% | ADD +27.6% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 293,358 | $1.1M | 3.3% | TRIM -26.6% |
| 7 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 278,589 | $1.1M | 3.1% | — |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 249,083 | $939.0K | 2.8% | — |
| 9 | VANGUARD FIDUCIARY TRUST CO | 240,925 | $908.3K | 2.7% | — |
| 10 | Russell Investments Group, Ltd. | 205,999 | $776.6K | 2.3% | DOUBLED +5585.9% |
| 11 | PANAGORA ASSET MANAGEMENT INC | 194,167 | $732.0K | 2.2% | ADD +81.6% |
| 12 | MORGAN STANLEY | 185,145 | $698.0K | 2.1% | — |
| 13 | CITADEL ADVISORS LLC | 135,303 | $510.1K | 1.5% | — |
| 14 | TWO SIGMA INVESTMENTS, LP | 127,109 | $479.2K | 1.4% | — |
| 15 | GOLDMAN SACHS GROUP INC | 126,390 | $476.5K | 1.4% | — |
| 16 | BANK OF AMERICA CORP /DE/ | 112,256 | $423.2K | 1.3% | TRIM -63.3% |
| 17 | Point72 Asset Management, L.P. | 98,738 | $372.2K | 1.1% | DOUBLED +130.1% |
| 18 | Trexquant Investment LP | 86,629 | $326.6K | 1.0% | DOUBLED +109.1% |
| 19 | ALLIANCEBERNSTEIN L.P. | 34,380 | $272.6K | 0.8% | — |
| 20 | Nuveen, LLC | 70,369 | $265.3K | 0.8% | ADD +48.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Russell Investments Group, Ltd. | DOUBLED | 3,623 | 205,999 | +5585.9% | $776.6K | 2026-Q1 |
| PANAGORA ASSET MANAGEMENT INC | ADD | 106,934 | 194,167 | +81.6% | $732.0K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 306,029 | 112,256 | -63.3% | $423.2K | 2026-Q1 |
| Point72 Asset Management, L.P. | DOUBLED | 42,906 | 98,738 | +130.1% | $372.2K | 2026-Q1 |
| Trexquant Investment LP | DOUBLED | 41,438 | 86,629 | +109.1% | $326.6K | 2026-Q1 |
| Nuveen, LLC | ADD | 47,520 | 70,369 | +48.1% | $265.3K | 2026-Q1 |
| MARSHALL WACE, LLP | ADD | 39,953 | 69,473 | +73.9% | $261.9K | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | DOUBLED | 15,800 | 55,100 | +248.7% | $207.7K | 2026-Q1 |
| Centiva Capital, LP | TRIM | 37,480 | 23,598 | -37.0% | $89.0K | 2026-Q1 |
| Invesco Ltd. | NEAR_EXIT | 352,005 | 13,038 | -96.3% | $49.2K | 2026-Q1 |
| CWM, LLC | ADD | 7,125 | 10,017 | +40.6% | $37.8K | 2026-Q1 |
| FMR LLC | TRIM | 13,043 | 8,328 | -36.1% | $31.4K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 154 | 564 | +266.2% | $2.1K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | TRIM | 128 | 92 | -28.1% | $347.00 | 2026-Q1 |
| Allworth Financial LP | DOUBLED | 12 | 65 | +441.7% | $246.00 | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 103,819 | 306,029 | +194.8% | $2.4M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 375,800 | 275,900 | -26.6% | $2.2M | 2025-Q4 |
| PANAGORA ASSET MANAGEMENT INC | ADD | 76,138 | 106,934 | +40.4% | $848.0K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 25,372 | 45,768 | +80.4% | $362.9K | 2025-Q4 |
| MetLife Investment Management, LLC | TRIM | 25,178 | 18,668 | -25.9% | $148.0K | 2025-Q4 |
| FMR LLC | ADD | 8,175 | 13,043 | +59.5% | $103.4K | 2025-Q4 |
| Allworth Financial LP | TRIM | 22 | 12 | -45.5% | $96.00 | 2025-Q4 |
| PANAGORA ASSET MANAGEMENT INC | DOUBLED | 31,919 | 76,138 | +138.5% | $261.9K | 2025-Q3 |
| Verition Fund Management LLC | TRIM | 20,009 | 11,600 | -42.0% | $39.9K | 2025-Q3 |
| Russell Investments Group, Ltd. | DOUBLED | 120 | 3,541 | +2850.8% | $12.2K | 2025-Q3 |
11 unique insiders with 20 transactions. Net insider value: -$308.2K ($68.8K bought, $377.0K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | Encrantz Staffan | Director | BUY | 14,100 | $4.88 | $68.8K |
| Jun 4, 2026 | Fountain Tamara | Director | AWARD | 28,261 | — | — |
| Jun 4, 2026 | Mazzacco Catherine | Director | AWARD | 28,261 | — | — |
| Jun 4, 2026 | Zurbay Donald | Director | AWARD | 28,261 | — | — |
| Jun 4, 2026 | Burbach Gerhard F | Director | AWARD | 28,261 | — | — |
| Jun 4, 2026 | Encrantz Staffan | Director | AWARD | 28,261 | — | — |
| May 18, 2026 | Bauerlein Alison | Chief Operating Officer | SELL | 12,728 | $5.12 | $65.2K |
| Apr 6, 2026 | HAYDEN JEREMY B. | Chief Legal Officer | SELL | 13,761 | $3.55 | $48.9K |
| Apr 6, 2026 | Rodberg James | Chief Financial Officer | SELL | 7,231 | $3.55 | $25.7K |
| Apr 2, 2026 | Badawi David | Chief Technology Officer | SELL | 8,168 | $3.48 | $28.4K |
| Apr 2, 2026 | Bauerlein Alison | Chief Operating Officer | SELL | 25,874 | $3.48 | $90.0K |
| Apr 1, 2026 | Badawi Paul | President and CEO | SELL | 29,244 | $3.70 | $108.2K |
| Apr 1, 2026 | Taylor Brenton | EVP, Operations & R&D | SELL | 2,869 | $3.70 | $10.6K |
| Feb 19, 2026 | Badawi David | Chief Technology Officer | EXERCISE | 21,270 | $0.2300 | $4.9K |
| Feb 3, 2026 | Bauerlein Alison | Chief Operating Officer | AWARD | 127,512 | — | — |
| Feb 3, 2026 | Taylor Brenton | EVP, Operations & R&D | AWARD | 100,464 | — | — |
| Feb 3, 2026 | Badawi David | Chief Technology Officer | AWARD | 64,915 | — | — |
| Feb 3, 2026 | HAYDEN JEREMY B. | Chief Legal Officer | AWARD | 115,920 | — | — |
| Feb 3, 2026 | Badawi Paul | President and CEO | AWARD | 154,560 | — | — |
| Feb 3, 2026 | Rodberg James | Chief Financial Officer | AWARD | 86,940 | — | — |
4 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 1 mixed, 1 neutral. Avg impact: 5.5/10.
BULLISH
8-K
8/10
Sight Sciences (SGHT) announced a final court judgment in its patent infringement lawsuit against Al
Apr 23, 2026
NEUTRAL
PRESS-RELEASE
3/10
Sight Sciences announced it will report Q1 2026 financial results on May 6, 2026, after market close
Apr 21, 2026
BEARISH
CLUSTER
5/10
Two insiders at Sight Sciences, including CEO Badawi Paul, sold shares in a coordinated cluster tota
Apr 3, 2026
MIXED
8-K
6/10
Sight Sciences reported Q4 2025 revenue growth of 7% to $20.4M, but full-year 2025 revenue declined
Mar 4, 2026
Current analyst consensus: Buy (71% buy). Based on 14 analysts: 4 strong buy, 6 buy, 4 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$8.54 mean target
+70.1% upside
Strong Buy (3.00)
$5.15 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $5.02 |
| Target Low | $5.15 |
| Target Mean | $8.54 |
| Target Median | $8.50 |
| Target High | $12.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.17 | $-0.17 | $-0.17 | 26.1% | +1.9% | 1↑ 0↓ | $0.0B | 10.9% | 1 |
| Next Q 2026-09-30 |
$-0.18 | $-0.18 | $-0.18 | -12.5% | -12.5% | 1↑ 0↓ | $0.0B | 10.6% | 1 |
| Current FY 2026-12-31 |
$-0.76 | $-0.76 | $-0.76 | 3.9% | -13.4% | 2↑ 1↓ | $0.1B | 11.2% | 1 |
| Next FY 2027-12-31 |
$-0.66 | $-0.66 | $-0.66 | 13.2% | -18.6% | 1↑ 0↓ | $0.1B | 11.2% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.170 | |
| 7d ago | $-0.173 | +0.003 |
| 30d ago | $-0.173 | +0.003 |
| 60d ago | $-0.154 | -0.016 |
| 90d ago | $-0.152 | -0.018 |
4 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 28, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Mar 6, 2026 | UBS | MAINTAIN | Buy | Buy |
| Mar 6, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Mar 2, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Jan 5, 2026 | Piper Sandler | UPGRADE | Neutral | Overweight |
| Dec 23, 2025 | UBS | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 6 | 4 | 0 | 0 | 71% | |
| May 1, 2026 | 4 | 6 | 4 | 0 | 0 | 71% | |
| Apr 1, 2026 | 4 | 6 | 4 | 0 | 0 | 71% | |
| Mar 1, 2026 | 4 | 6 | 4 | 0 | 0 | 71% | |
| Feb 1, 2026 | 4 | 6 | 4 | 0 | 0 | 71% | |
| Jan 1, 2026 | 3 | 5 | 5 | 0 | 0 | 62% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 6, 2026
earnings
Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance
<p align="justify">MENLO PARK, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an
May 6, 2026
earnings_calendar
SGHT Q1 2026 Earnings Scheduled — 2026-05-06
Apr 23, 2026
short_volume
Short Volume: SGHT — 91.7% short (2.1M / 2.3M)
Short: 2,064,066 | Exempt: 830 | TRF Vol: 2,251,322 | Short Ratio: 91.7% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
other
Sight Sciences Announces the Release of its Sustainability Report
The Sustainability Report provides data for 2023 through 2025 on the Company’s environmental, social, and governance initiatives <pre>The Sustainabili
Apr 21, 2026
earnings
Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026
<p align="justify">MENLO PARK, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an ey
Apr 1, 2026
routine
Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
<p align="justify">MENLO PARK, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an e
Mar 30, 2026
other
Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th
<p align="justify">MENLO PARK, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=eTLk7KhZf8_zPQLNupKhMH
Mar 30, 2026
other
Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent
Court preserves jury’s finding of willful infringement by Alcon, and awards past damages to Sight Sciences in excess of $34 million and ongoing royalt
Mar 4, 2026
earnings
Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance
<p align="justify"> MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"),
Mar 4, 2026
earnings_calendar
SGHT Q4 2025 Earnings After Market Close — 2026-03-04